Answers are grounded in this paper and cite their sources.
Evaluates monoclonal antibody mixtures for quantifying ApoA-I in human serum, suggesting improved IVD consistency.
Antibodies serve as essential recognition elements in in vitro diagnostics (IVD), yet reliance on polyclonal antibodies (pAbs) introduces significant challenges related to batch-to-batch consistency. To address this, we employed a de novo sequencing platform, which identified 15 candidate monoclonal antibody (mAb) sequences. From these, four distinct mAb mixtures were formulated and evaluated. Using an immunoturbidimetric assay to quantify apolipoprotein A-I (ApoA-I) in 105 human serum samples, the performance of these mixtures was compared to that of a conventional pAb reagent. The four-mAb mixture demonstrated excellent correlation with the pAb assay (Passing-Bablok: y = 1.0536x-0.0748 g/L; r 2 = 0.994). This optimized cocktail successfully replaced the pAb reagent, matching or exceeding its performance in key analytical parameters including linearity, sensitivity, and precision. Our work thus establishes a practical pathway for converting heterogeneous pAbs into defined, recombinant antibody reagents suitable for standardized IVD applications.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: